Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 19;10(5):e003890. doi: 10.1136/jitc-2021-003890

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

CD163+ cell tumor infiltration is correlated with poor clinical outcome. (A) Representative images of lung cancer sample stained with the multiplexed panel CD8/CD163/CK7—Objective 20× (B–C) Kaplan-Meier curves of progression-free survival (B) and overall survival (C) according to stroma CD8+ cell density. (D) Proportion of patients who experienced durable clinical benefit (DCB) or non-clinical benefit (NCB) according to their level of CD8+ stroma infiltration classified as high and low. P value was calculated using χ² test.(E–F) Kaplan-Meier curves of progression-free survival (E) and overall survival (F) according to tumor CD163 +cell density. (G) Proportion of patients who experienced DCB or NCB according to their level of CD163+ tumor infiltration classified as high and low. P value was calculated using χ² test.